Latest News

Savaria Corporation has released its full-year 2025 results, reporting CAD$913.53 million in sales and CAD$68.77 million in net income, with basic earnings per share from continuing operations of CAD$0.96. The combination of higher sales and a meaningful lift in earnings per share suggests the company converted top-line growth into improved profitability during 2025. We’ll now examine how this stronger full-year profitability, including higher earnings per share, may influence Savaria’s...

NIKE (NKE) is back in focus after Barclays shifted to a more positive stance on the stock, citing operational progress, cleaner financial metrics, and tighter management discipline ahead of key upcoming earnings. See our latest analysis for NIKE. Despite Barclays turning more positive, the recent 30 day share price return of a 12.69% decline and the 90 day share price return of a 16.09% decline show momentum has been weak, and the 1 year total shareholder return of a 22.93% loss points to an...

Planet Labs PBC (PL) has drawn investor attention after a recent double digit one-day move, adding to gains over the past month and past 3 months, prompting a closer look at its current setup. See our latest analysis for Planet Labs PBC. That 10.1% 1 day share price return and 20.8% 30 day share price return feed into a much bigger move, with momentum reinforced by a 64.4% 90 day share price return and a very large 1 year total shareholder return. If you are interested in what else is moving...

Insulet (PODD) is in focus after disclosing an internal tubing defect in certain Omnipod 5 Pod lots, prompting a voluntary Medical Device Correction and free replacements. Production and new patient starts are expected to continue. See our latest analysis for Insulet. The tubing defect news has landed against a weak recent share price backdrop, with the 90 day share price return at a 20.4% decline and the 1 year total shareholder return at an 11.5% loss. This suggests that momentum has been...

Vermilion Energy Inc. recently reported its 2025 results, showing revenue of CA$1,765.14 million alongside a net loss of CA$653.60 million, while also updating production guidance, raising its quarterly dividend to CA$0.135 per share, and advancing its share buyback program. Despite reporting a larger loss, Vermilion meaningfully increased total production to 119,919 boe/d for 2025 and continued to return capital through higher dividends and ongoing repurchases, underlining an emphasis on...

In March 2026, Aldeyra Therapeutics reported that the FDA issued a Complete Response Letter for its reproxalap dry eye disease NDA, citing insufficient and inconsistent evidence of efficacy despite no safety or manufacturing concerns. An important nuance is that the FDA did not request new trials, instead urging Aldeyra to clarify why certain studies failed and where reproxalap might work best. We’ll now examine how the FDA’s efficacy concerns and lack of requested new trials reshape...

Visional (TSE:4194) has posted Q2 2026 revenue of ¥23.3b and basic EPS of ¥97.56, with its trailing twelve month EPS at ¥444.64 and revenue at ¥89.8b, setting a clear earnings bar for investors following the name this quarter. Over recent periods the company has seen revenue move from ¥71.6b and EPS of ¥336.95 in the trailing twelve months to Q2 2025 to ¥89.8b and EPS of ¥444.64 in the latest trailing window, giving you a cleaner read on how the top line and EPS have tracked into the current...

In early 2026, a joint SONAR and Ryder System report showed tender rejection rates climbing to nearly 14.3% in early February, reaching levels last seen during the pandemic and pointing to tightening trucking capacity. This spike in rejection rates hints at a shifting freight balance that could influence pricing power and operational conditions for logistics providers like Ryder. We’ll now examine how this jump in tender rejection rates could influence Ryder’s existing investment narrative...

Evercore recently expanded its healthcare and biotechnology advisory platform, adding senior biotechnology-focused banker David Ke to its equity capital markets group in New York and featuring senior healthcare banker Bennett Blau at the 2026 Life Science Intelligence Summit. These moves highlight Evercore’s push to deepen sector expertise and client reach in biotechnology and life sciences at a time when healthcare capital formation remains a key focus for global investment banks. Now we’ll...

In recent days, IBM has unveiled an industry-first quantum-centric supercomputing reference architecture, expanded its AI collaboration with NVIDIA, and completed an approximately US$11.00 billion acquisition of data-streaming firm Confluent to strengthen its hybrid cloud and AI data platform. Together, these moves deepen IBM’s role at the intersection of quantum computing, high-performance AI infrastructure, and real-time enterprise data, potentially reshaping how large organizations build...

Vertiv Holdings Co (NYSE:VRT) has partnered with NVIDIA to deliver converged infrastructure for AI factory deployments. The collaboration introduces simulation ready digital power and cooling assets into NVIDIA's Vera Rubin DSX AI factory reference design and Omniverse DSX Blueprint. The goal is to speed up and de risk large scale AI projects through validated, repeatable, digitally coordinated infrastructure modules. For investors tracking AI infrastructure, this partnership provides...

Impinj recently entered privately negotiated agreements to repurchase approximately US$40.2 million of its 1.125% convertible notes due 2027 for cash, leaving about US$57.3 million outstanding after the March 16, 2026 closing. This sizable debt repurchase alters Impinj’s capital structure and could influence how investors assess its balance sheet strength and financial flexibility. Next, we’ll examine how Impinj’s sizable convertible note repurchase affects its existing investment narrative...

Earlier this month, Tenaya Therapeutics announced a research collaboration with Alnylam Pharmaceuticals to validate up to 15 gene targets for cardiovascular disease, receiving an upfront US$10 million payment, cost reimbursement over two years, and eligibility for as much as US$1.13 billion in development and commercial milestones. The collaboration highlights Alnylam’s effort to extend its RNAi platform into cardiovascular indications while outsourcing early target validation to a...

ATS (TSX:ATS) is back in focus after announcing a collaboration with Kistler Group to build a high-speed medical device assembly line with real-time quality checks, traceability and compliance-focused process monitoring. See our latest analysis for ATS. The collaboration news arrives as ATS trades at CA$42.0, with a 1-day share price return of 6.19% and a 90-day share price return of 14.22%. The 3-year total shareholder return of negative 24.93% contrasts with a 5-year total shareholder...

Max Stock (TASE:MAXO) closed out FY 2025 with fourth quarter revenue of ₪352.6 million and basic EPS of ₪0.22, alongside trailing 12 month revenue of ₪1.43 billion and EPS of ₪0.89 that frame the year in terms of both scale and earnings power. Over the past few reporting periods, the company has seen quarterly revenue move from ₪373.1 million in Q3 2024 to ₪352.6 million in Q4 2025, with basic EPS ranging between ₪0.17 and ₪0.29 across FY 2025. This gives investors a clear read on how sales...

Latest FY 2026 results snapshot Advance Residence Investment (TSE:3269) has just wrapped up FY 2026 with total revenue of ¥20.7b and basic EPS of ¥3,232 in the second half, capping a year in which trailing twelve month revenue came in at ¥41.2b and EPS of ¥6,435. Over recent periods, revenue has moved from ¥18.4b in the second half of FY 2025 to ¥20.7b in the second half of FY 2026, while trailing EPS has shifted from ¥5,285 to ¥6,435. This sets the context for a year where net profit margins...

If you are wondering whether Rhythm Pharmaceuticals at around US$87.68 is still reasonably priced after its run, you are not alone. This article takes a closer look at what that level might mean for value focused investors. The stock has seen a 5.7% decline over the past week and a 10.6% decline over the last month, even after a 67.7% return over the past year and a very large gain over three years of about 4x. Recent coverage has highlighted investor interest following these sizeable multi...

T-Mobile US (NasdaqGS:TMUS) is collaborating with NVIDIA to pilot distributed edge AI infrastructure across its 5G network. The pilot aims to support real-time AI workloads for use cases such as smart cities, utilities, facility management, and industrial safety. This move extends T-Mobile's role from a traditional wireless carrier to a platform provider for enterprise-grade edge AI computing. T-Mobile US, trading at around $213.35, sits at the center of a broad shift where connectivity and...

Renasant (RNST) has drawn fresh attention after its recent share performance, with the stock down about 13% over the past month and 5% over the past 3 months, despite positive 1 year total returns. See our latest analysis for Renasant. The recent 13.4% 1 month share price decline, on top of a 5.4% 3 month share price fall, contrasts with Renasant's 4.6% 1 year total shareholder return. This suggests near term momentum is fading even as longer term investors remain modestly ahead. If you are...

AbbVie (NYSE:ABBV) is facing a revived whistleblower lawsuit alleging violations of the U.S. False Claims Act tied to federal drug pricing. The case brings renewed attention to AbbVie’s pricing practices within government programs and its potential legal exposure. Separately, AbbVie has entered a new multi year antibody discovery collaboration with Alloy Therapeutics. The Alloy agreement focuses on antibody discovery platforms intended to support AbbVie’s work on biologics and difficult drug...

Procter & Gamble (PG) is back in focus after rolling out premium upgrades across flagship brands, including Pampers AMORE diapers with five layer protection and higher absorbency, as well as deeper cleaning Swiffer PowerMop pads. See our latest analysis for Procter & Gamble. Despite the stream of premium launches across Pampers, Swiffer, Mr. Clean and BEVEL, the 30 day share price return of Procter & Gamble is a 5.37% decline, while its year to date share price return of 6.83% and 5 year...

Why the upcoming board meeting matters for ICBC shareholders Industrial and Commercial Bank of China (SEHK:1398) has called a board meeting for 27 March 2026 in Beijing to approve its 2025 annual results and review dividend arrangements. This meeting provides an updated view of the bank’s profitability, capital management and potential cash returns. As a result, the stock often comes into focus ahead of such announcements. See our latest analysis for Industrial and Commercial Bank of...

In recent days, director Estienne de Klerk increased his holding in Growthpoint Properties Australia by purchasing 65,000 stapled securities on market, lifting his stake to 1,940,457 units. This additional personal investment strengthens alignment between board and investors, highlighting governance stability and a clear financial commitment from leadership. We’ll now explore how this increased director ownership might influence Growthpoint Properties Australia’s existing investment...

Chocoladefabriken Lindt & Sprüngli (SWX:LISN) has drawn fresh attention after releasing full year 2025 results, showing higher sales, revenue and net income, and announcing an annual dividend of CHF 1,800 per share. See our latest analysis for Chocoladefabriken Lindt & Sprüngli. At a share price of CHF 112,800, Chocoladefabriken Lindt & Sprüngli has seen a 7 day share price return of 0.71%, while the 30 day share price return of an 8.14% decline contrasts with a 5 year total shareholder...